首页|HoxB3、JAG1在肾细胞癌患者中的表达水平及对临床预后的影响

HoxB3、JAG1在肾细胞癌患者中的表达水平及对临床预后的影响

扫码查看
目的 探讨肾细胞癌患者癌组织中同源异型盒基因B3(HoxB3)、JAG1的表达水平及对临床预后的影响.方法 选取2017年1月至2020年1月在本院收治的93例肾细胞癌患者作为观察组,收集肾细胞癌患者的癌组织标本(肾细胞癌组)及对应的癌旁组织标本(癌旁组).采用免疫组化法检测肾细胞癌患者的HoxB3、JAG1表达水平.分析HoxB3、JAG1表达与肾细胞癌患者的临床病理特征关系,采用多因素Cox回归分析影响肾细胞癌患者预后的相关因素.结果 肾细胞癌组的HoxB3阳性表达率低于癌旁组,JAG1阳性表达率高于癌旁组(均P<0.001).共有62例患者存活,存活率为66.67%.低分化、TNM分期Ⅲ~Ⅳ期、Fuhrman分级Ⅲ~Ⅳ级、有淋巴结转移、有肾包膜受侵的肾细胞癌患者的HoxB3阳性表达率及JAG1阴性表达率低于中/高分化、TNM分期I~Ⅱ期、Fuhrman分级Ⅰ~Ⅱ级、无淋巴结转移、无肾包膜受侵的肾细胞癌患者.低分化、TNM分期Ⅲ~Ⅳ期、Fuhrman分级Ⅲ~Ⅳ级、有淋巴结转移、有肾包膜受侵的肾细胞癌患者的3年生存率均降低(均P<0.05).HoxB3阳性表达、JAG1阴性表达患者的3年生存率高于HoxB3阴性表达、JAG1阳性表达患者[28(80.00%)vs.34(58.62%),18(85.71%)vs.44(61.11%),均 P<0.05].TNM 分期Ⅲ~Ⅳ期、有淋巴结转移、HoxB3 阴性表达、JAG1阳性表达是肾细胞癌患者预后的危险因素(均P<0.05).结论 HoxB3在肾细胞癌中呈低表达,JAG1在肾细胞癌中呈高表达,二者均与肾细胞癌的临床病理特征及预后密切相关,可作为肾细胞癌预后评估的生物学标志物.
Expression levels of HoxB3 and JAG1 in renal cell carcinoma tissues and their effects on clinical prognosis
Objective To explore the expression levels of homeobox gene B3(HoxB3)and JAG1 in renal cell carcinoma tissues and their effects on clinical prognosis.Methods A total of 93 patients with renal cell carcinoma admitted to our hospital from January 2017 to January 2020 were se-lected as the observation group,and the cancer tissue specimens of renal cell carcinoma patients(renal cell carcinoma group)and the corresponding paracancerous tissue specimens(paracancerous group)were collected.Immunohistochemistry was used to detect the expression levels of HoxB3 and JAG1 in renal cell carcinoma tissues and adjacent tissues.The relationship between the expression of HoxB3 and JAG1 and the clinicopathological characteristics of patients with renal cell carcinoma was analyzed.Multivariate Cox regression was used to analyze the related factors affecting the prognosis of patients with renal cell carcinoma.Results The positive expression rate of HoxB3 in renal cell carcinoma group was lower than that in paracancerous group,and the positive expression rate of JAG1 was higher than that in paracancerous group(all P<0.001).A total of 62 patients survived,with a survival rate of 66.67%.The HoxB3 positive expression rate and JAG1 negative expression rate in renal cell carci-noma patients with poorly differentiated,TNM stage Ⅲ-Ⅳ,Fuhrman grade Ⅲ-Ⅳ,lymph node metas-tasis and renal envelope invasion were lower than those in middle/highly differentiated renal cell carci-noma patients with TNM stage Ⅰ-Ⅱ,Fuhrman grade Ⅰ-Ⅱ,no lymph node metastasis and renal en-velope invasion,and the 3-year survival rate was higher than that of patients with poorly differentiated renal cell carcinoma,TNM stage Ⅲ-Ⅳ,Fuhrman grade Ⅲ-Ⅳ,lymph node metastasis,renal enve-lope invasion,HoxB3 negative expression and JAG1 positive expression(all P<0.05).The 3-year survival rate of patients with HoxB3 positive expression and JAG1 negative expression was higher than that of patients[28(80.00%)vs.34(58.62%),18(85.71%)vs.44(61.11%),all P<0.05].TNM stage Ⅲ-Ⅳ,lymph node metastasis,negative expression of HoxB3 and positive expression of JAG1 were risk factors for prognosis of patients with renal cell carcinoma(all P<0.05).Conclusions The expression of HoxB3 is low in renal cell carcinoma,and JAG1 is high in renal cell carcinoma.Both of them are closely related to the clinicopathological characteristics and prognosis of patients with renal cell carcinoma,and can be used as biological markers for the prognosis evaluation of renal cell carcinoma.

Carcinoma,Renal CellHomologous Heterobox Gene B3JAG1

贾琴、林博宁、王璧椒

展开 >

广汉市人民医院病理科,广汉 618300

癌,肾细胞 同源异型盒基因B3 JAG1

2024

国际泌尿系统杂志
中华医学会,湖南省医学会

国际泌尿系统杂志

CSTPCD
影响因子:0.414
ISSN:1673-4416
年,卷(期):2024.44(3)
  • 20